|
CZ20003798A3
(cs)
|
1998-04-15 |
2001-08-15 |
Aventis Pharmaceuticals Products, Inc. |
Způsob výroby cyklických peptidů vázaných k polymernímu nosiči
|
|
US6316410B1
(en)
*
|
1999-09-22 |
2001-11-13 |
National Research Council Of Canada |
Parathyroid hormone analogues for the treatment of osteoporosis
|
|
AU2003233286A1
(en)
*
|
2002-05-16 |
2003-12-02 |
Theratechnologies Inc. |
Pth derivatives resistant to skin proteases
|
|
WO2004073587A2
(en)
*
|
2003-02-19 |
2004-09-02 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
|
|
AU2004257362A1
(en)
*
|
2003-07-15 |
2005-01-27 |
National Research Council Of Canada |
Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
|
|
US7439226B2
(en)
*
|
2003-09-30 |
2008-10-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Serine protease inhibitors
|
|
US20060127320A1
(en)
*
|
2004-05-10 |
2006-06-15 |
Nastech Pharmaceutical Company Inc. |
Method of delivering parathyroid hormone to a human
|
|
US20060052306A1
(en)
*
|
2004-05-10 |
2006-03-09 |
Nastech Pharmaceutical Company Inc. |
GRAS composition for enhanced mucosal delivery of parathyroid hormone
|
|
US20060052305A1
(en)
*
|
2004-05-10 |
2006-03-09 |
Nastech Pharmaceutical Company Inc. |
Method of treating osteoporosis using intranasal parathyroid hormone
|
|
CA2567056A1
(en)
*
|
2004-05-10 |
2005-12-08 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of parathyroid hormone
|
|
US9051379B2
(en)
|
2005-07-07 |
2015-06-09 |
Fulcrum Sp Ltd. |
Sp1 polypeptides, modified Sp1 polypeptides and uses thereof
|
|
US20070173447A1
(en)
*
|
2005-10-25 |
2007-07-26 |
Nastech Pharmaceutical Company Inc. |
Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
|
|
CA2628945A1
(en)
*
|
2005-11-10 |
2007-05-24 |
Board Of Control Of Michigan Technological University |
Black bear parathyroid hormone and methods of using black bear parathyroid hormone
|
|
US20080051332A1
(en)
*
|
2005-11-18 |
2008-02-28 |
Nastech Pharmaceutical Company Inc. |
Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
|
|
BRPI0719885B8
(pt)
*
|
2006-10-13 |
2021-05-25 |
Lilly Co Eli |
peptídeos peguilados como moduladores de receptores de pth, seus usos, e composição.
|
|
EP2391377A2
(en)
|
2009-02-02 |
2011-12-07 |
Ramot at Tel-Aviv University Ltd. |
Peptides, pharmaceutical compositions comprising same and uses thereof
|
|
AU2010231514A1
(en)
|
2009-04-01 |
2011-11-03 |
Rappaport Family Institute For Research In The Medical Sciences |
A method of regulating proliferation and differentiation of keratinocytes
|
|
WO2010116375A1
(en)
|
2009-04-08 |
2010-10-14 |
Yeda Research And Development Co. Ltd. |
Isolated peptides for regulating apoptosis
|
|
US20120070449A1
(en)
|
2009-05-28 |
2012-03-22 |
Yeda Research And Development Co. Ltd. |
Methods of treating inflammation
|
|
US8999932B2
(en)
|
2009-07-29 |
2015-04-07 |
Kai Pharmaceuticals, Inc. |
Therapeutic agents for reducing parathyroid hormone levels
|
|
BR112012013725A2
(pt)
|
2009-12-07 |
2017-01-10 |
Univ Michigan Tech |
paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
|
|
US9352000B2
(en)
|
2010-05-05 |
2016-05-31 |
Rappaport Family Institute For Research In The Medical Sciences |
Use of CCL1 in therapy
|
|
MX358161B
(es)
*
|
2010-05-13 |
2018-08-06 |
The General Hospital Corp Star |
Analogos de hormona paratiroidea y usos para los mismos.
|
|
WO2012017439A2
(en)
|
2010-08-04 |
2012-02-09 |
Ramot At Tel-Aviv University Ltd. |
Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
|
|
WO2012131680A2
(en)
|
2011-03-28 |
2012-10-04 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for treating inflammation
|
|
EP2721686B1
(en)
*
|
2011-06-17 |
2018-11-28 |
NantEnergy, Inc. |
Ionic liquid containing sulfonate ions
|
|
CA2866358C
(en)
|
2012-03-06 |
2020-06-23 |
Cellect Biotechnology Ltd. |
Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof
|
|
US9695402B2
(en)
|
2013-09-17 |
2017-07-04 |
Yeda Research And Development Co. Ltd. |
ERK-derived peptides and uses thereof
|
|
US20160340659A1
(en)
|
2014-01-30 |
2016-11-24 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. |
Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same
|
|
EP3122768A2
(en)
|
2014-03-27 |
2017-02-01 |
Yeda Research and Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
|
US20180036382A1
(en)
|
2015-02-09 |
2018-02-08 |
Entera Bio Ltd. |
Formulations for oral administration of active agents with controlled absorption profile
|
|
EP3261582B1
(en)
|
2015-02-26 |
2021-01-06 |
Remodeless CV Ltd. |
Methods and compositions relating to leptin antagonists
|
|
US10786547B2
(en)
|
2015-07-16 |
2020-09-29 |
Biokine Therapeutics Ltd. |
Compositions, articles of manufacture and methods for treating cancer
|
|
WO2017122209A2
(en)
|
2016-01-12 |
2017-07-20 |
Yeda Research And Development Co. Ltd. |
NF-kappaB INHIBITORS
|
|
IL243838A
(en)
|
2016-01-28 |
2017-07-31 |
Sp Nano Ltd |
The composition containing sp1 protein and carbon nanoparticles and its uses
|
|
IL243839B
(en)
|
2016-01-28 |
2018-01-31 |
Sp Nano Ltd |
Conductive wires
|
|
US11820833B2
(en)
|
2016-06-05 |
2023-11-21 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Peptides that inhibit binding of EPCR to its ligand to treat inflammation
|
|
WO2018037416A1
(en)
|
2016-08-25 |
2018-03-01 |
Yeda Research And Development Co. Ltd. |
Methods and compositions for treating autoimmune diseases
|
|
KR20190091192A
(ko)
|
2016-12-01 |
2019-08-05 |
라모트 앳 텔-아비브 유니버시티 리미티드 |
신경 손상의 병용 치료제
|
|
WO2018185768A1
(en)
|
2017-04-07 |
2018-10-11 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Hair care compositions
|
|
WO2018216011A1
(en)
|
2017-05-23 |
2018-11-29 |
Technion Research & Development Foundation Limited |
Agents which inhibit gads dimerization and methods of use thereof
|
|
EP3655009B1
(en)
|
2017-07-20 |
2023-10-11 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Nanoparticle compositions
|
|
IL253642A0
(en)
|
2017-07-24 |
2017-09-28 |
Seger Rony |
Combined treatment for cancer
|
|
IL253984A0
(en)
|
2017-08-14 |
2017-09-28 |
Yeda Res & Dev |
Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
|
|
IL274979B2
(en)
|
2017-11-29 |
2024-07-01 |
Univ Ramot |
Methods for the prevention and treatment of neurogenic seizures
|
|
JP7350019B2
(ja)
|
2018-05-31 |
2023-09-25 |
イミュニティ ファルマ リミテッド |
筋萎縮性側索硬化症（ａｌｓ）を治療するための組成物、及び治療のためにそれを使用する方法
|
|
KR102945860B1
(ko)
|
2018-07-11 |
2026-03-31 |
카 메디컬 리미티드 |
SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
|
|
IL265486A
(en)
|
2019-03-19 |
2020-09-30 |
Yeda Res & Dev |
Type II stable opsins and methods of using them
|
|
IL266728B
(en)
|
2019-05-19 |
2020-11-30 |
Yeda Res & Dev |
Identification of recurrent mutant neopeptides
|
|
US20220267409A1
(en)
|
2019-07-11 |
2022-08-25 |
Kahr Medical Ltd. |
Heterodimers and methods of use thereof
|
|
IL268111A
(en)
|
2019-07-16 |
2021-01-31 |
Fainzilber Michael |
Methods of treating pain
|
|
IL270800A
(en)
|
2019-11-20 |
2021-05-31 |
Yeda Res & Dev |
A method for treating Alzheimer's disease
|
|
KR20220151168A
(ko)
|
2020-02-09 |
2022-11-14 |
엔엘씨 파르마 엘티디 |
Sars-cov-2에 대한 신속한 검출 테스트
|
|
EP4114473A1
(en)
|
2020-03-05 |
2023-01-11 |
Ariel Scientific Innovations Ltd. |
Anti-hemorrhaging compositions
|
|
US20230127559A1
(en)
|
2020-03-16 |
2023-04-27 |
Yeda Research And Development Co. Ltd. |
Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
|
|
IL276599A
(en)
|
2020-08-09 |
2022-03-01 |
Yeda Res & Dev |
T cell receptor unique to mage-a1 and its uses
|
|
IL276627A
(en)
|
2020-08-10 |
2022-03-01 |
Yeda Res & Dev |
Compositions for diagnosis and treatment of coronavirus infections
|
|
WO2022064494A2
(en)
|
2020-09-23 |
2022-03-31 |
Yeda Research And Development Co. Ltd. |
Methods and compositions for treating coronaviral infections
|
|
EP4225903A1
(en)
|
2020-10-07 |
2023-08-16 |
Protalix Ltd. |
Long-acting dnase
|
|
MX2023005235A
(es)
|
2020-11-03 |
2023-10-16 |
Protalix Ltd |
Uricasa modificada y usos de la misma.
|
|
IL305315A
(en)
|
2021-02-18 |
2023-10-01 |
Yeda res & development co ltd |
Methods for producing vaccines
|
|
IL283563A
(en)
|
2021-05-30 |
2022-12-01 |
Yeda Res & Dev |
Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
|
|
WO2023031934A1
(en)
|
2021-09-02 |
2023-03-09 |
Yeda Research And Development Co. Ltd. |
Agents that target the glycine arginine-rich domain of nucleolin and uses thereof
|
|
WO2024038462A1
(en)
|
2022-08-17 |
2024-02-22 |
Yeda Research And Development Co. Ltd. |
Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor
|
|
WO2024241314A1
(en)
|
2023-05-22 |
2024-11-28 |
Neomanna Ltd |
Black soldier fly protein extracts
|